Leukaemia Trial, Recruiting NCT06792994 Sponsor: German CLL Study Group Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT06792994
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be willing to sign a consent form that has been approved by an ethics committee.
  • You must have been officially diagnosed with a type of blood cancer called CLL (chronic lymphocytic leukemia) at the time you joined one of the qualifying first-line treatment studies.
  • Your first treatment for CLL must have been given as part of one of three specific German CLL study group trials: CLL13, CLL14, or CLL17.
  • Any treatments you received after your first treatment must have either been recorded during your participation in one of those studies, or you must agree to have those treatments documented as part of this observational trial.
  • You must be willing and able to follow the steps and procedures required by this trial.

Who may not be able to join:

  • You cannot join if you did not previously take part in one of the three qualifying German CLL study group trials (CLL13, CLL14, or CLL17).
  • You cannot join if you are legally considered unable to make your own decisions.
  • You cannot join if you are currently living in a facility by order of a court or government authority.
  • You cannot join if you have a close personal or financial relationship with the organisation running the trial or the doctor overseeing it (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: BArbara F. Eichhorst, MD, Uniklinik Köln

Phone: +4922147888220

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
German CLL Study Group
Registry
ClinicalTrials.gov
Start date
2 April 2026
Est. completion
1 August 2030

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov